Aspira Women's Health Amends 8-K Filing on Key Agreements, Equity Sales
Ticker: AWHL · Form: 8-K/A · Filed: Jan 26, 2024 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $3.50, $4.255, $4.13, $0.125 |
| Sentiment | mixed |
Complexity: moderate
Sentiment: mixed
Topics: amendment, equity-sales, corporate-governance, material-agreement
TL;DR
**Aspira Women's Health just amended an 8-K, signaling changes to key agreements and equity sales.**
AI Summary
Aspira Women's Health Inc. filed an 8-K/A on January 26, 2024, amending a previous filing from January 24, 2024. This amendment primarily updates information regarding an entry into a material definitive agreement, results of operations and financial condition, unregistered sales of equity securities, material modifications to rights of security holders, and financial statements and exhibits. While the specific details of these changes are not provided in this excerpt, the filing indicates ongoing corporate activity that could impact the company's financial health and shareholder structure. Investors should pay attention to the full details of the underlying 8-K to understand the implications for their investment.
Why It Matters
This filing indicates that Aspira Women's Health Inc. is actively engaged in corporate actions that could affect its financial standing and the value of its shares. Understanding the specifics of these amendments is crucial for investors to assess potential risks and opportunities.
Risk Assessment
Risk Level: medium — The filing mentions 'unregistered sales of equity securities' and 'material modifications to rights of security holders,' which can dilute existing shares or alter shareholder power, posing a medium risk.
Analyst Insight
Investors should seek out the full, unamended 8-K filing and its original version to understand the specific details of the material definitive agreement, equity sales, and modifications to security holder rights. This will allow for a comprehensive assessment of the impact on the company's financial health and shareholder value.
Key Numbers
- 001-34810 — Commission File Number (Identifies Aspira Women's Health Inc. with the SEC)
- 33-0595156 — IRS Employer Identification No. (Identifies Aspira Women's Health Inc. for tax purposes)
Key Players & Entities
- Aspira Women's Health Inc. (company) — the registrant filing the 8-K/A
- 0000926617 (company) — Central Index Key (CIK) for Aspira Women's Health Inc.
- 001-34810 (company) — Commission File Number for Aspira Women's Health Inc.
- 33-0595156 (company) — IRS Employer Identification No. for Aspira Women's Health Inc.
- January 24, 2024 (date) — Date of earliest event reported in the filing
FAQ
What is the purpose of this 8-K/A filing by Aspira Women's Health Inc.?
This 8-K/A filing is an amendment to a previous 8-K, updating information related to an entry into a material definitive agreement, results of operations and financial condition, unregistered sales of equity securities, material modifications to rights of security holders, and financial statements and exhibits, as indicated by the 'ITEM INFORMATION' sections.
When was the earliest event reported in this 8-K/A filing?
The earliest event reported in this 8-K/A filing occurred on January 24, 2024, as stated under 'Date of Report (Data of earliest event reported): January 24, 2024'.
What specific items are being amended or updated in this 8-K/A?
The filing lists several items being updated: 'Entry into a Material Definitive Agreement', 'Results of Operations and Financial Condition', 'Unregistered Sales of Equity Securities', 'Material Modifications to Rights of Security Holders', and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for Aspira Women's Health Inc.?
The Central Index Key (CIK) for Aspira Women's Health Inc. is 0000926617, as listed under 'COMPANY DATA'.
Where is Aspira Women's Health Inc.'s principal executive office located?
Aspira Women's Health Inc.'s principal executive office is located at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738, as detailed in the 'BUSINESS ADDRESS' section.
Filing Stats: 1,772 words · 7 min read · ~6 pages · Grade level 11.7 · Accepted 2024-01-26 17:19:59
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
- $3.50 — tain Purchasers at an offering price of $3.50 per share and accompanying Purchase War
- $4.255 — to Ms. Sandford at an offering price of $4.255 per share and accompanying Purchase War
- $4.13 — q Capital Market on January 24, 2024 of $4.13 per share plus $0.125 per Purchase Warr
- $0.125 — anuary 24, 2024 of $4.13 per share plus $0.125 per Purchase Warrant. The purchase pric
- $0.0001 — Warrant is sold in this Offering, minus $0.0001. The gross proceeds to the Company from
- $5.5 m — fering are expected to be approximately $5.5 million, before deducting placement agent
- $13.20 — 366,664 shares at an exercise price of $13.20 per share and a termination date of Aug
- $2.6 million — port that the Company had approximately $2.6 million in cash and cash equivalents, excluding
- $0.3 million — uivalents, excluding restricted cash of $0.3 million as of December 31, 2023. The Company ha
- $0.88 — tion 2(b) of each Original Warrant from $0.88 (which had automatically adjusted to $1
Filing Documents
- d699303d8ka.htm (8-K/A) — 41KB
- d699303dex11.htm (EX-1.1) — 39KB
- d699303dex41.htm (EX-4.1) — 80KB
- d699303dex42.htm (EX-4.2) — 84KB
- d699303dex43.htm (EX-4.3) — 8KB
- d699303dex51.htm (EX-5.1) — 14KB
- d699303dex101.htm (EX-10.1) — 209KB
- g699303g0125141403439.jpg (GRAPHIC) — 2KB
- 0001193125-24-016864.txt ( ) — 737KB
- awh-20240124.xsd (EX-101.SCH) — 3KB
- awh-20240124_lab.xml (EX-101.LAB) — 19KB
- awh-20240124_pre.xml (EX-101.PRE) — 12KB
- d699303d8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Placement Agency Agreement dated January 24, 2024, by and between Aspira Women's Health Inc. and A.G.P./Alliance Global Partners 4.1 Form of Pre-Funded Warrant to Purchase Common Stock 4.2 Form of Warrant to Purchase Common Stock 4.3 Form of Warrant Amendment to Common Stock Purchase Warrant 5.1 Opinion of Cooley LLP 10.1 Form of Securities Purchase Agreement, dated January 24, 2024, by and between Aspira Women's Health Inc. and the purchasers party thereto 23.1 Consent of Cooley LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: January 26, 2024 By: /s/ Nicole Sandford Nicole Sandford Chief Executive Officer, President and Director